Related Experiment Videos
Noninvasive risk stratification after myocardial infarction: rationale, current evidence and the need for definitive
1Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Ablerta. exner@ucalgary.ca
Insights
Identifying patients after myocardial infarction (MI) who need an implantable cardioverter defibrillator (ICD) to prevent sudden cardiac death from ventricular tachycardia (VT) or ventricular fibrillation (VF) remains challenging. Current methods are limited, necessitating further research into predictive tools.
Area of Science:
- Cardiology
- Electrophysiology
- Sudden Cardiac Death Prevention
Background:
- Despite advances, sudden cardiac death from ventricular tachycardia (VT) or ventricular fibrillation (VF) post-myocardial infarction (MI) remains a significant issue.
- Implantable cardioverter defibrillators (ICDs) are effective but selecting appropriate patients is challenging.
- Current selection criteria, including left ventricular (LV) dysfunction and invasive testing, identify only a subset of at-risk individuals.
Purpose of the Study:
- To review the challenges and current strategies for identifying post-MI patients who would benefit from prophylactic ICD implantation.
- To explore the potential of noninvasive risk stratification tools for improving patient selection.
- To highlight the need for randomized trials to validate new risk assessment methods.
Main Methods:
- Review of existing literature on risk stratification for sudden cardiac death after MI.
- Analysis of current guidelines and limitations for ICD implantation.
- Discussion of emerging noninvasive assessment techniques, including cardiac structure, conduction, repolarization, and autonomic modulation.
Main Results:
- Significant LV dysfunction and inducible VT/VF during invasive testing are the only proven methods for guiding prophylactic ICD therapy in the nonacute post-MI period.
- Existing noninvasive risk stratification tools have not yet demonstrated proven clinical utility.
- A combination of noninvasive assessments may offer improved risk prediction, but requires further validation.
Conclusions:
- Reliable identification of post-MI patients who will benefit from ICDs remains a major clinical challenge.
- While promising, noninvasive risk stratification tools require validation through randomized controlled trials.
- Until then, established methods of LV dysfunction and invasive testing remain the standard for guiding prophylactic ICD therapy.
Abstract:
Despite advances in therapies for myocardial infarction (MI), death attributed to a cardiac arrest from ventricular tachycardia (VT) or ventricular fibrillation (VF) remains an important problem. The implantable cardioverter defibrillator (ICD) is effective in preventing death from VT/VF, but reliably identifying which post-MI patients would benefit from an ICD remains a major challenge. Beyond the initial post-MI period, the presence of significant left ventricular (LV) dysfunction, alone or in combination with the induction of sustained VT/VF during invasive testing, is the only proven means of selecting patients for a prophylactic ICD. However, these approaches identify only a fraction of those at risk. Furthermore, most patients with significant LV dysfunction after MI have a low, near-term risk of VT/VF. Noninvasive risk stratification tools have been developed to better identify patients likely to benefit from an ICD. To date, none of these tools has been proven useful in this regard. The factors leading to a cardiac arrest are complex, and a single test is unlikely to reliably predict risk. Noninvasive assessment of cardiac structure, conduction and repolarization along with autonomic modulation appear to be useful in predicting the risk of a cardiac arrest after MI, particularly when assessed in combination. However, randomized trials assessing the efficacy of ICD therapy in patients identified as being at risk are required. Until such data are available, significant LV dysfunction alone and in combination with the induction of VT/VF during invasive testing in the nonacute post-MI period remain the only proven methods to guide prophylactic ICD therapy.
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:30Acute Coronary Syndrome I: Introduction
01:27Myocarditis II: Clinical Features and Diagnostic Tests
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...